- BioNotebook: IPOs abound as Dicerna, Celladon launch; Puma seeks $115m; Omeros looks to Phase IIb
- Industry and regulators clash in debate over trial data disclosure
- US Capitol Capsule: Rare disease sector matures; FDA keeping pace?
- 5 Questions for: gene therapy developer Celladon's CEO
ANALYSIS Other Informa Analysis